Company: LCTX
Filing Date: 2025-04-29
Form Type: DEFA14A
Source: 0000950170-25-060123
Chunk: 1

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEFA14A
Chunk 1
---
 Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before June 16, 2025. Internet: www.investorelections.com/LCTX Call: 1-866-648-8133 Email: paper@investorelections.com * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number located below in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. SEE REVERSE FOR FULL AGENDA Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved

Lineage Cell Therapeutics, Inc. Annual Meeting of Shareholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR EACH DIRECTOR NOMINEE LISTED AND FOR ON PROPOSALS 2, 3 AND 4. PROPOSAL 1. To elect seven directors to hold office until the 2026 annual meeting of shareholders and until their respective successors are duly elected and qualified. 1.01 Dipti Amin 1.02 Deborah Andrews 1.03 Neal C. Bradsher 1.04 Brian M. Culley 1.05 Anula Jayasuriya 1.06 Michael H. Mulroy 1.07 Angus C. Russell 2. To ratify the appointment of Moss Adams LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025. 3. To approve, on an advisory basis, the compensation paid to our named executive officers. 4. To approve an amendment to the Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan to increase the number of common shares available thereunder by 19,500,000. Note: Other business may be transacted which properly come before the meeting or any adjournment or postponement thereof.